Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial

Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial

Abstract Background Stereotactic ablative radiotherapy (SABR) has become an established treatment option for medically-inoperable early-stage (Stage I-IIA) non-small cell lung cancer (ES-NSCLC). SABR is able to obtain high rates of local control with low rates of symptomatic toxicity in this patient...

Full description

Bibliographic Details
Main Authors: David A. Palma, Hanbo Chen, Houda Bahig, Stewart Gaede, Stephen Harrow, Joanna M. Laba, X. Melody Qu, George B. Rodrigues, Brian P. Yaremko, Edward Yu, Alexander V. Louie, Inderdeep Dhaliwal, Christopher J. Ryerson
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Cancer
Subjects:
Stereotactic radiotherapy
Cancer
Lung
Interstitial lung disease
Toxicity
Survival
Online Access:https://doi.org/10.1186/s12885-019-6392-8

Internet

https://doi.org/10.1186/s12885-019-6392-8

Similar Items